recombinant human hyaluronidase
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07484893 | May → Aug 2026 overdue | — | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT00782587 | Oct 2008 → Mar 2009 | superficial urinary bladder carcinoma | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01928030 | Dec 2013 → Nov 2015 | cancer, lymphedema | Stanford University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00782106 | Dec 2006 → Nov 2007 | immunodeficiency disease | Baxalta now part of Shire | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01485796 | Dec 2011 → Jan 2013 | immunodeficiency disease | Baxalta now part of Shire | Completed | No outcome recorded |
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT05084053 | Jan 2022 → Oct 2025 | chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT02955355 | Nov 2016 → Jul 2023 | chronic inflammatory demyelinating polyradiculoneuropathy | Baxalta now part of Shire | Completed | No outcome recorded |
| Phase 3 | NCT00814320 | Dec 2008 → Nov 2010 | immunodeficiency disease | Baxalta now part of Shire | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT01120431 | May 2010 | — | Baxter Healthcare Corporation | Withdrawn | No outcome recorded Stop: Business |
| Comparator or background therapy12 trials | ||||||
| Phase 1 | NCT07391670 Background | Mar 2026 → Aug 2027 expected | cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT07161414 Background | Nov 2025 → Jul 2027 expected | cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT06622005 Background | Apr 2025 → Apr 2027 expected | plasma cell myeloma | Roswell Park Cancer Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT02519452 Background | Oct 2015 → Dec 2017 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT05340309 Background | Dec 2022 → Dec 2026 expected | non-small cell lung carcinoma | University of Southern California | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07388524 Background | Mar 2027 → Sep 2032 expected | non-small cell lung carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 3 | NCT05513586 Background | Sep 2022 → Oct 2025 | immunodeficiency disease | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT03301220 Background | Nov 2017 → May 2024 | smoldering plasma cell myeloma | Janssen Research & Development, LLC | Completed | Met primary |
| Phase 3 | NCT03277313 Background | Sep 2017 → Jul 2022 | immunodeficiency disease | Baxalta now part of Shire | Completed | No outcome recorded |
| Phase 3 | NCT02549170 Background | Dec 2015 → Feb 2022 | chronic inflammatory demyelinating polyradiculoneuropathy | Baxalta now part of Shire | Completed | Met primary |
| Phase 4 | NCT00773175 Comparator | Oct 2008 → Nov 2009 | — | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 4 | NCT00656370 Background | Dec 2007 → Jan 2008 | — | Halozyme Therapeutics | Completed | No outcome recorded |
Press releases naming this drug 39 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Hyaluronidase | “1800 milligram (mg) of daratumumab co-formulated with 2000 units per milliliter (U/mL) of recombinant human hyaluronidase (rHuPH20) by subcutaneous (SC) injection” NCT03301220 ↗20“Participants will receive HYQVIA/HyQvia SC which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).” NCT02549170 ↗ “Participants received HYQVIA/HyQvia SC which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).” NCT02955355 ↗ “TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20).” NCT05084053 ↗ “Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)” NCT03277313 ↗ “recombinant human hyaluronidase, (an investigational synthetic enzyme also known as rHuPH20)” NCT00782587 ↗ “Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)” NCT05513586 ↗ “durvalumab + recombinant human hyaluronidase (rHu) dose” NCT07391670 ↗ |
| Known as | HLXTE-HAase02 | “HLXTE-HAase02 is a proprietary recombinant human hyaluronidase, with a molecular weight of approximately 49 kDa, is expressed in Chinese Hamster Ovary (CHO) cells and is...” NCT07484893 ↗ |
| Known as | Hylenex | “Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)” NCT00656370 ↗ |
| Known as | rHu | “durvalumab + recombinant human hyaluronidase (rHu) dose” NCT07391670 ↗1“Recombinant Human Hyaluronidase (rHu)” NCT07161414 ↗ |
| Known as | rHuPH20 | “1800 milligram (mg) of daratumumab co-formulated with 2000 units per milliliter (U/mL) of recombinant human hyaluronidase (rHuPH20) by subcutaneous (SC) injection” NCT03301220 ↗8“Participants will receive HYQVIA/HyQvia SC which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).” NCT02549170 ↗ “Participants received HYQVIA/HyQvia SC which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).” NCT02955355 ↗ “TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20).” NCT05084053 ↗ “recombinant human hyaluronidase, (an investigational synthetic enzyme also known as rHuPH20)” NCT00782587 ↗ “Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)” NCT05513586 ↗ “recombinant human hyaluronidase (rHuPH20) increases SC tissue permeability” PMID 22846381 ↗ Jul 2012 “Recombinant Human Hyaluronidase [rHuPH20]) SC Administration” NCT02519452 ↗ “rHuPH20” NCT01928030 ↗ |
| Known as | rHuPH20 = Recombinant Human Hyaluronidase | “rHuPH20 = Recombinant Human Hyaluronidase” NCT00782106 ↗ |
| Modality | Protein / enzyme biologic | “preceded by human recombinant hyaluronidase (hylenex) 150 units” NCT00656370 ↗ |
| Route | Subcutaneous | “SC administration with hylenex (150 Units)” NCT00773175 ↗ |